首页> 外文期刊>The American Journal of Human Genetics >Mutations in the 5' UTR of ANKRD26, the ankirin repeat domain 26 gene, cause an autosomal-dominant form of inherited thrombocytopenia, THC2.
【24h】

Mutations in the 5' UTR of ANKRD26, the ankirin repeat domain 26 gene, cause an autosomal-dominant form of inherited thrombocytopenia, THC2.

机译:锚蛋白重复域26基因ANKRD26的5'UTR中的突变导致遗传性血小板减少症THC2的常染色体显性形式。

获取原文
获取原文并翻译 | 示例
       

摘要

THC2, an autosomal-dominant thrombocytopenia described so far in only two families, has been ascribed to mutations in MASTL or ACBD5. Here, we show that ANKRD26, another gene within the THC2 locus, and neither MASTL nor ACBD5, is mutated in eight unrelated families. ANKRD26 was also found to be mutated in the family previously reported to have an ACBD5 mutation. We identified six different ANKRD26 mutations, which were clustered in a highly conserved 19 bp sequence located in the 5' untranslated region. Mutations were not detected in 500 controls and are absent from the 1000 Genomes database. Available data from an animal model and Dr. Watson's genome give evidence against haploinsufficiency as the pathogenetic mechanism for ANKRD26-mediated thrombocytopenia. The luciferase reporter assay suggests that these 5' UTR mutations might enhance ANKRD26 expression. ANKRD26 is the ancestor of a family of primate-specific genes termed POTE, which have been recently identified as a family of proapoptotic proteins. Dysregulation of apoptosis might therefore be the pathogenetic mechanism, as demonstrated for another thrombocytopenia, THC4. Further investigation is needed to provide evidence supporting this hypothesis.
机译:迄今为止,仅在两个家族中描述的常染色体显着性血小板减少症THC2归因于MASTL或ACBD5中的突变。在这里,我们显示ANKRD26,THC2位点内的另一个基因,既不是MASTL也不是ACBD5,在八个无关家族中发生了突变。还发现ANKRD26在先前报道具有ACBD5突变的家族中发生了突变。我们鉴定了六个不同的ANKRD26突变,它们聚集在位于5'非翻译区的高度保守的19 bp序列中。在500个对照中未检测到突变,而1000个基因组数据库中没有突变。来自动物模型和沃森博士基因组的可用数据提供了针对单倍剂量不足作为ANKRD26介导的血小板减少症的致病机制的证据。萤光素酶报告基因测定表明,这些5'UTR突变可能会增强ANKRD26的表达。 ANKRD26是称为POTE的灵长类动物特异性基因家族的祖先,最近已将其鉴定为促凋亡蛋白家族。因此,凋亡的失调可能是其发病机制,如另一种血小板减少症THC4所证明的。需要进一步调查以提供支持该假设的证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号